Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cortistatin is an endogenous cyclic neuropeptide that shares high structural homology with somatostatin but possesses distinct biological functions. It acts as a potent agonist for all five somatostatin receptors (SSTR1-5) and also interacts with the ghrelin receptor (GHSR1a) and the Mas-related gene X2 (MrgX2). Cortistatin is involved in regulating sleep, neuronal activity, and immune responses. In the context of oncology, particularly prostate cancer, it has been shown to inhibit cell proliferation and migration in androgen-independent models by modulating AKT and JNK signaling pathways. It also exhibits potent anti-inflammatory and immunomodulatory properties, making it a candidate for treating autoimmune and inflammatory conditions like sepsis and rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cortistatin.